• The University's research capabilities are greatly enhanced by participation in strong, international, national and regional research networks. View the University’s internationally recognised centres of research excellence.


  • The University of Liverpool is one of the UK’s leading research institutions with an annual turnover of £435 million, including £114 million for research.

  • The University of Liverpool is internationally recognised for excellence in biomedical research with expertise in key research the areas of cancer, Infection, Personalised Medicines, Drug Safety Science and Medicines for Children.


The University is globally recognised for its research in health and life sciences, science and engineering, and humanities and social sciences.

Investment in innovative research has seen the development of interdisciplinary research centres including the National Centre for Zoonosis Research and the Stephenson Institute for Renewable Energy.

University of Liverpool research is contributing to some of the most pressing challenges facing the world today. It has brought together internationally renowned researchers from across its faculties of health and life sciences, science and engineering, and humanities and social sciences to conduct research that has significant impact on global policy, the environment, and the lives of people from across the world.



  • The University of Liverpool has excellent research facilities within the Faculty of Health and Life Sciences. These are available with excellent technical support to external users from industry and other academic institutions.

    The role of the University's Technology Directorate is to provide and maintain an accessible and up to date research infrastructure within the Faculty of Health and Life Sciences.

    Bringing together high‐tech and high throughput analytical facilities and technologies under a single, academic‐led Technology Directorate creates an opportunity to manage the University investment and ensures that all members of the Faculty can access facilities, ensuring that their research is competitive and has high impact.

    The following facilities are offered via the Technology Directorate:

  • The Centre for Cell Imaging is equipped with four confocal microscopes - one system dedicated for luminescence imaging and two photothermal microscopes. In addition there are a series of image analysis workstations, with high speed data handling and storage capability.

  • The cell sorting facility contains a FACSAria II cell sorter - upgraded to include ultra-violet and yellow-green lasers which has the capability for four way cell sorting on any combination of 15 fluorescence parameters. Alongside this sorter the facility houses a FACSCanto flow cytometer to meet the needs of investigators who want to separate out labelled cell populations without collecting them. The FACsCanto has three lasers allowing up to 10 parameters to be used for flow cytometric analysis of cells.

  • The NMR Shared Research Facility works alongside the high–field NMR Centre for Structural Biology. The Centre houses 800MHz and 600MHz solution state NMR spectrometers, in addition to a 400MHz solid state spectrometer. The Centre has recently established a metabolomics capacity to serve an increasing need both within the Faculty and the wider research community.

  • The Proteomics Facility works alongside the highly successful Protein Function Group. The facility operates 11 mass spectrometry platforms that support a wide range of techniques. The centre offers more than just world class technology; staff offer full consultancy and support, from experimental planning to data analysis, ensuring the best quality data from the most appropriate techniques.

  • The potential for investigating pure cell populations has never been greater as individual cell types can be analysed by a variety of downstream techniques such as genomics and proteomics. The Leica LMD7000 Laser Microdissection microscope offers a means of isolating single cell types, or even single cells from tissues.  It achieves this by combining a highly specified microscope with a laser so precise that it can cut around a single live cell.  The LMD7000 is a state of the art instrument and represents a major improvement in the way this technology operates. 

  • Measuring the kinetics of biochemical reactions – the speed and extent to which they occur - is a crucial part of many research projects. Housed in the Enzyme Assay Screening Facility (EASF) the EZ Reader is a unique instrument that combines laser fluorescence detection and Capillary Zone Electrophoresis to measure enzyme activity towards fluorescently labelled synthetic substrates, often peptides.

  • As a NERC UK service provider and an MRC genomics hub, the Centre for Genomic Research (CGR) has a nationally recognised reputation. Since 2008 it has collaborated in over 60 peer-reviewed publications and raised more than £17 million in research income. The centre recently sequenced and analysed the notoriously complex wheat genome, an undertaking that won it international recognition.


  • The University of Liverpool has entered into an agreement with Redx Oncology and the Royal Liverpool and Broadgreen University Hospitals Trust (RLBUHT) to provide valuable support to the Liverpool Tissue Bank (LTB). Redx Oncology is a private company, which develops novel anti-cancer drugs, and was launched in April last year. It is based at laboratories within the Royal Liverpool University Hospital. The LTB is a University of Liverpool and RLBUHT resource, where samples from consented patients with cancer are collected.
  • Liverpool Science Park is a not for profit company owned by Liverpool John Moore’s University, the University of Liverpool and Liverpool City Council. Liverpool Science Park (LSP) is home to over 75 companies drawn from a variety of knowledge intensive sectors including graduate startups, key commercial facing R&D facilities and a handful of relevant business support companies.
  • The University, alongside the Liverpool School of Tropical Medicine and Royal Liverpool Broadgreen University Hospital NHS Trust is a key partner in the development of the Liverpool BioInnovation Centre; a £28m project that will place Liverpool alongside Boston and Singapore as a leading centre in life sciences. The Centre will sit alongside the planned new £451m Royal Liverpool Hospital, and is expected to open in 2014.


  • In an innovative industry-adademia collaboration with AstraZeneca new expertise in cardiovascular toxicity is being developed at the MRC Centre for Drug Safety Science.



  • The University of Liverpool has one of the largest biomedical communities in the United Kingdom and is the only higher education institution with education and research spanning the biosciences, medicine, dentistry, health sciences, tropical medicine and veterinary science.
  • The University of Liverpool is a Russell Group Institution, rated in the world's top 1% of higher education institutions.
  • The University has an annual research income of £150m.
  • The University has produced 9 Nobel Laureates in 100 years.


  • The University of Liverpool has been awarded a share of the Government's £1 billion investment to establish Europe's first materials Innovation Factory with Unilever.
  • The University has a £3 million NHS Chair in Pharmacogenetics - the first and only such position in the country.

Foundation Building
Brownlow Hill
L69 3BX


Staff 4700
Go Back

Sign up for our newsletter


Sign up to receive our free, quarterly e-mail newsletter for news and information from LHP

We won’t use your details for any other purpose, and we won’t pass them on to any other organisation.